Effient

(Prasugrel)

ApprovedSmall molecule

Prasugrel is used to reduce the risk of heart attack and stroke in patients with acute coronary syndrome (a sudden decrease in blood flow to the heart), particularly those undergoing a procedure to open blocked heart arteries.[2] Effient is currently approved and in use across 14 indications[4].[1]

Effient is one of 236 small molecule programs targeting Recurrent thrombophlebitis. It is currently in Approved.

Indications

125

Total Trials

Active Trials

235

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Recurrent ThrombophlebitisActive, not recruiting

ST Elevation Myocardial InfarctionApproved

Chronic Renal Failure SyndromeApproved

AsthmaApproved

Cardiac ArrestActive, not recruiting

Platelet AggregationActive, not recruiting

Acute Coronary SyndromeCompleted

Coronary Artery DiseaseCompleted

Myocardial InfarctionCompleted

Acute Myocardial InfarctionCompleted

Recurrent ThrombophlebitisApproved

Active, not recruiting

ST Elevation Myocardial InfarctionApproved

Approved

Chronic Renal Failure SyndromeApproved

Approved

AsthmaApproved

Approved

Cardiac ArrestApproved

Active, not recruiting

Platelet AggregationApproved

Active, not recruiting

Acute Coronary SyndromeApproved

Completed

Coronary Artery DiseaseApproved

Completed

Myocardial InfarctionApproved

Completed

Acute Myocardial InfarctionApproved

Completed

Showing 10 of 13 indications

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Effient

CCosette Pharmaceuticals, Inc.

Celexa

1 3

Paracetamol

GSK

Preclinical

1 4

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 5

Aclidinium Bromide

Atrovent

2 7

Ozone

TTanta University

Preclinical

1 8

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 9

Guanidine Hydrochloride

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Rhinovirus

UUniversity of Virginia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Dual Antiplatelet Therapy

NCT06691191

Q1 2027

Post-ApprovalRecruiting

Dual Antiplatelet Therapy

NCT06821191

Q2 2027

Post-ApprovalRecruiting

Percutaneous Coronary Intervention

NCT06916520

Q4 2027

Post-ApprovalRecruiting

Dual Antiplatelet Therapy

NCT07025148

Clinical

Trials by Indication[1]

Acute Coronary Syndrome19 trials

The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00385944·56 enrolled

A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00830960·720 enrolled

Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome

Completed·GGyeongsang National University Hospital·Phase 4·NCT01951001·255 enrolled

Show 16 more trials

Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome

Completed·UUniversity of Cologne·Phase 3·NCT01774838·49 enrolled

Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Completed·UUniversity of Patras·Phase 4·NCT01642966·56 enrolled

Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

Completed·KKorea University Anam Hospital·Phase 4·NCT02487732·60 enrolled

Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

Terminated·IIndiana University·Phase 4·NCT01612884·67 enrolled

Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)

Completed·—·Phase 3·NCT02944123·120 enrolled

A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00097591·13,619 enrolled

Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial

Completed·LLMU Klinikum·Phase 4·NCT01959451·2,600 enrolled

Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT03672097·204 enrolled

Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome

Completed·DDeutsches Herzzentrum Muenchen·Phase 4·NCT01944800·4,018 enrolled

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00699998·9,326 enrolled

Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01115738·282 enrolled

Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT01107899·29 enrolled

Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention

Completed·UUniversity of Patras·Phase 3·NCT01360437·44 enrolled

Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome

Unknown status·GGennaro Sardella·Phase 3·NCT01778842·68 enrolled

PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants

Completed·—·Phase 3·NCT01641510·70 enrolled

Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome-a Stepped Wedge Cluster Randomized Evaluation in the SWEDEHEART-registry

Completed·VVastra Gotaland Region·Approved·NCT05183178·17,095 enrolled

Myocardial Infarction10 trials

Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction

Unknown status·DDeutsches Herzzentrum Muenchen·Phase 4·NCT00976092·548 enrolled

Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Completed·UUniversity of Patras·Phase 4·NCT01463163·50 enrolled

Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction

Completed·—·Phase 4·NCT03387826·20 enrolled

Show 7 more trials

Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction

Terminated·—·Phase 3·NCT02075125·39 enrolled

Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse

Completed·UUniversità degli Studi di Ferrara·Phase 3·NCT01336348·100 enrolled

PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus

Completed·GGennaro Sardella·Phase 3·NCT01531114·50 enrolled

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Completed·UUniversity of Florida·Phase 4·NCT02545933·130 enrolled

Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor

Completed·CCollegium Medicum w Bydgoszczy··NCT03454841·73 enrolled

Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)

Completed·UUniversity of Patras·Phase 3·NCT01338909·35 enrolled

Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)

Completed·OOttawa Heart Institute Research Corporation·Phase 2/3·NCT01452139·102 enrolled

Coronary Artery Disease8 trials

Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)

Unknown status·SSeoul National University Hospital·Phase 4·NCT02193971·3,384 enrolled

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

Completed·UUniversity of Florida·Phase 4·NCT04006288·90 enrolled

Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01107912·155 enrolled

Show 5 more trials

Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment

Completed·UUniversity of Patras·Phase 3·NCT01304472·25 enrolled

The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT01260584·110 enrolled

Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease

Completed·UUniversity of Florida·N/A·NCT01852175·110 enrolled

Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01107925·72 enrolled

Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease

Completed·UUniversity of Patras·Phase 4·NCT01957540·22 enrolled

Clopidogrel7 trials

Prasugrel/Clopidogrel Maintenance Dose Washout Study

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 4·NCT01014624·56 enrolled

VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel

Completed·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 4·NCT01684813·65 enrolled

The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel

Completed·MMedstar Health Research Institute·Phase 4·NCT01365221·77 enrolled

Show 4 more trials

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00356135·139 enrolled

Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI

Completed·LLene Holmvang·Phase 4·NCT01135667·106 enrolled

Cangrelor to Clopidogrel or Prasugrel Transition Study

Completed· Novartis logo

Novartis·Phase 2·NCT01979445·15 enrolled

High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients

Completed·UUniversity of Roma La Sapienza·Phase 3·NCT01543932·81 enrolled

Percutaneous Coronary Intervention6 trials

Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)

Recruiting·JJ.P.S Henriques·Phase 4·NCT06916520·300 enrolled

Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention

Terminated·RRoyal Brompton & Harefield NHS Foundation Trust·Phase 4·NCT01339026·44 enrolled

Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study

Completed·GGermano Di Sciascio·Phase 4·NCT05643586·50 enrolled

Show 3 more trials

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00357968·201 enrolled

Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention

Completed·—·Phase 3·NCT01609647·76 enrolled

Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention

Completed·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT01505790·187 enrolled

45 more indications

Platelet Reactivity4 trials

Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor

Unknown status·LLifeBridge Health·Phase 4·NCT01869309·400 enrolled

Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial

Completed·GGennaro Sardella·Phase 3·NCT01465828·30 enrolled

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT00910299·423 enrolled

Show 1 more trial

Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity

Completed·UUniversity of Pecs·Phase 4·NCT01493999·147 enrolled

Antiplatelet3 trials

P3AMI Antiplatelet Trial

Completed·TThe Royal Wolverhampton Hospitals NHS Trust·Phase 4·NCT02376283·87 enrolled

Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data

Completed·—··NCT05086081·28,389 enrolled

Replication of the TRITON-TIMI Antiplatelet Trial in Healthcare Claims Data

Completed·—··NCT04237922·43,864 enrolled

Dual Antiplatelet Therapy3 trials

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

Recruiting·UUniversity of Florida·Phase 4·NCT07025148·40 enrolled

Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study

Recruiting·UUniversity of Florida·Phase 4·NCT06821191·78 enrolled

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Recruiting·UUniversity of Florida·Phase 4·NCT06691191·48 enrolled

Sickle Cell Disease3 trials

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Terminated· Eli Lilly logo

Eli Lilly·Phase 3·NCT01794000·341 enrolled

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01476696·33 enrolled

Prasugrel Versus Placebo in Adult Sickle Cell Disease

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01167023·62 enrolled

Percutaneous Coronary Intervention (PCI)3 trials

A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00059215·905 enrolled

Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).

Completed·UUniversity of Patras·Phase 3·NCT01109784·70 enrolled

Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)

Completed·UUniversity of Patras·Phase 4·NCT01463150·27 enrolled

Interaction3 trials

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Completed·VViatris Innovation GmbH·Phase 1·NCT03430661·77 enrolled

Pharmacokinetic Interaction Between Ritonavir and Prasugrel in Healthy Volunteers

Completed·UUniversity Hospital, Geneva·Phase 1·NCT01346800·10 enrolled

Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.

Completed·AAscopharm Groupe Novasco·N/A·NCT01175200·82 enrolled

Platelet Function3 trials

Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

Completed·TTufts Medical Center·Phase 4·NCT01789814·24 enrolled

Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate

Completed·DDavid Vivas·Phase 1·NCT02243137·30 enrolled

Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing

Unknown status·DDeutsches Herzzentrum Muenchen·Phase 4·NCT01456364·70 enrolled

Function2 trials

A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:

Completed·UUniversity of Florida·Phase 4·NCT02065479·65 enrolled

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

Completed·UUniversity of Florida·Phase 4·NCT03489863·14 enrolled

Drug2 trials

Rapid Activity of Platelet Inhibitor Drugs Study 2

Completed·DDavid Antoniucci·Phase 4·NCT01805570·50 enrolled

Rapid Activity of Platelet Inhibitor Drugs Study

Completed·—·Phase 4·NCT01510171·50 enrolled

Itching2 trials

Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor

Completed·UUniversity of Florida·N/A·NCT02016170·82 enrolled

Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI

Completed·UUniversity of Florida·Phase 4·NCT04668144·359 enrolled

STEMI2 trials

CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI

Completed·MMaasstad Hospital·Phase 4·NCT03296540·729 enrolled

Pharmacological Effects of Crushing Prasugrel in STEMI Patients

Completed·UUniversity of Florida·Phase 4·NCT02212028·52 enrolled

Acute Myocardial Infarction2 trials

Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction

Completed·FFaculty Hospital Kralovske Vinohrady·Phase 4·NCT02808767·1,226 enrolled

Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor

Unknown status·AAmsterdam UMC, location VUmc·Phase 4·NCT02422888·110 enrolled

Atrial Fibrillation2 trials

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT02866175·1,506 enrolled

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01830543·2,124 enrolled

Endothelial Function2 trials

Ticagrelor and Endothelial Function

Unknown status·HHotel Dieu de France Hospital·Phase 4·NCT02261922·20 enrolled

Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)

Completed·EErasmus Medical Center·Phase 4·NCT02587260·54 enrolled

Injury1 trial

Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI

Completed·AAORTICA Group·N/A·NCT03435133·61 enrolled

Treatment1 trial

Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI

Completed·SStiftung Institut fuer Herzinfarktforschung·Phase 3·NCT01327534·63 enrolled

Aneurysm1 trial

Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm

Completed·SSeoul National University Hospital·Phase 4·NCT03581409·198 enrolled

Oral1 trial

A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01430091·18 enrolled

Antiretroviral Treatment1 trial

Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients

Terminated·JJules Desmeules·Phase 1·NCT03054207·21 enrolled

Respiratory Disease1 trial

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)

Completed·EElliot Israel, MD·Phase 2·NCT01597375·46 enrolled

Optical Coherence Tomography1 trial

Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy

Completed·—·Phase 2·NCT04766437·75 enrolled

Intensive Care Unit1 trial

High "on Treatment" Platelet Reactivity in the Intensive Care Unit

Unknown status·MMedical University of Vienna·Phase 2·NCT02285751·200 enrolled

Antiplatelet Drug1 trial

Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention

Terminated·LLMU Klinikum·Phase 4·NCT02548611·795 enrolled

High Bleeding Risk1 trial

Clopidogrel Monotherapy in Patients With High Bleeding Risk

Completed·MMayo Clinic·Phase 4·NCT05223335·98 enrolled

Non-ST Elevation Myocardial Infarction1 trial

A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01015287·4,033 enrolled

Randomized1 trial

Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT02978040·122 enrolled

Chronic Asthma1 trial

The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma

Completed·UUniversity of Milan·Phase 4·NCT01305369·26 enrolled

Cardiac Arrest1 trial

Add-on Cangrelor in STEMI-triggered Cardiac Arrest

Unknown status·MMedical University of Vienna·Phase 4·NCT03273075·60 enrolled

Coronary Artery Bypass1 trial

The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency

Unknown status·PPrince Sultan Cardiac Center, Adult Cardiology Department.·Phase 3·NCT01598337·200 enrolled

Diabetes1 trial

Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes

Completed·UUniversity of Florida·N/A·NCT01852214·50 enrolled

Coagulation1 trial

The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation

Completed·MMedical University of Vienna·Phase 4·NCT01099566·20 enrolled

Clinical Trial1 trial

Clinical Trial to Characterize Pharmacokinetic-pharmacodynamic (PKPD) of Prasugrel 10 mg or 30 mg in Healthy Volunteers

Unknown status·—·Phase 1·NCT02075268·8 enrolled

RCT1 trial

Ticagrelor vs. Prasugrel Effects on Infarct Size

Withdrawn·YYochai Birnbaum·Phase 2·NCT02507323

Thrombolysis1 trial

Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis

Completed·FFederal University of São Paulo·Phase 4·NCT02215993·50 enrolled

Antiplatelet Therapy1 trial

Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study

Completed·JJohannes Gutenberg University Mainz·Phase 4·NCT01700322·126 enrolled

Platelet Aggregation1 trial

Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel

Completed·UUniversity of Sao Paulo·Phase 4·NCT05247385·87 enrolled

Elderly1 trial

The Elderly ACS II Trial

Completed·AAzienda USL Reggio Emilia - IRCCS·Phase 4·NCT01777503·1,457 enrolled

Adult1 trial

An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01178099·26 enrolled

Diabetes Mellitus1 trial

Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00642174·35 enrolled

Hemodialysis1 trial

Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis

Completed·UUniversity of Patras·Phase 3·NCT01155765·70 enrolled

Prevention1 trial

Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis

Completed·VVA Office of Research and Development·Phase 3·NCT01560780·84 enrolled

Myocardial Infarction (MI)1 trial

Strategies for Antiplatelet Management Following Acute Coronary Syndrome

Recruiting·IInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz·Approved·NCT07507500·8,100 enrolled

Migraine1 trial

Cessation of Migraine Headaches With Patent Foramen Ovale-Directed Therapy (COMFORT - PFO): An Investigator-Initiated Study

Not yet recruiting·CColumbia University·Phase 3·NCT07629635·32 enrolled

Acute Myocardial Infarction (AMI)1 trial

Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction

Completed·BBrigham and Women's Hospital··NCT07610577·377,753 enrolled

Unspecified9 trials

A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response

Withdrawn·CCirQuest Labs, LLC·Phase 4·NCT03027934

Prasugrel With Lower Dose - Loading Dose

Completed·—·Phase 3·NCT02070159·43 enrolled

Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)

Unknown status·GGyeongsang National University Hospital·Phase 4·NCT04734353·492 enrolled

Show 6 more trials

Prasugrel Re-load Strategies

Completed·UUniversity of Florida·Phase 4·NCT01201772·65 enrolled

Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study

Completed·UUniversity of Patras·Phase 4·NCT01642940·30 enrolled

TAXUS Libertē Post Approval Study

Completed·BBoston Scientific Corporation··NCT00997503·4,199 enrolled

Cangrelor Prasugrel Transition Study

Completed· Novartis logo

Novartis·Phase 2·NCT01852019·12 enrolled

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study

Terminated·UUniversity of Maryland, Baltimore·Phase 4·NCT01452152·9 enrolled

Study of Prasugrel in Korean Healthy Male Volunteers

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01591317·30 enrolled

Regulatory

FDA Approval Timeline[5]

Jul 10, 2009

EFFIENT

NDA NDA022307

Jul 10, 2009

EFFIENT

NDA NDA022307

Dec 6, 2010

EFFIENT

NDA NDA022307

Sep 27, 2011

EFFIENT

NDA NDA022307

Mar 23, 2012

EFFIENT

NDA NDA022307

Nov 30, 2012

EFFIENT

NDA NDA022307

Oct 16, 2013

EFFIENT

NDA NDA022307

Nov 19, 2013

EFFIENT

NDA NDA022307

Jul 7, 2015

EFFIENT

NDA NDA022307

Jan 14, 2016

EFFIENT

NDA NDA022307

Jul 12, 2016

EFFIENT

NDA NDA022307

Mar 9, 2018

EFFIENT

NDA NDA022307

Mar 28, 2019

EFFIENT

NDA NDA022307

Dec 22, 2020

EFFIENT

NDA NDA022307

Sources

References

[1]
ClinicalTrials.gov — 125 trial records for Prasugrel. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Effient drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Prasugrel compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Prasugrel. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022307). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Cosette Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Purinergic Receptor P2Y12 Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: CCosette Pharmaceuticals, Inc.

Effient

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q4 2027

Trials by Indication[1]

Acute Coronary Syndrome19 trials

Myocardial Infarction10 trials

Coronary Artery Disease8 trials

Clopidogrel7 trials

Percutaneous Coronary Intervention6 trials

Platelet Reactivity4 trials

Antiplatelet3 trials

Dual Antiplatelet Therapy3 trials

Sickle Cell Disease3 trials

Percutaneous Coronary Intervention (PCI)3 trials

Interaction3 trials

Platelet Function3 trials

Function2 trials

Drug2 trials

Itching2 trials

STEMI2 trials

Acute Myocardial Infarction2 trials

Atrial Fibrillation2 trials

Endothelial Function2 trials

Injury1 trial

Treatment1 trial

Aneurysm1 trial

Oral1 trial

Antiretroviral Treatment1 trial

Respiratory Disease1 trial

Optical Coherence Tomography1 trial

Intensive Care Unit1 trial

Antiplatelet Drug1 trial

High Bleeding Risk1 trial

Non-ST Elevation Myocardial Infarction1 trial

Randomized1 trial

Chronic Asthma1 trial

Cardiac Arrest1 trial

Coronary Artery Bypass1 trial

Diabetes1 trial

Coagulation1 trial

Clinical Trial1 trial

RCT1 trial

Thrombolysis1 trial

Antiplatelet Therapy1 trial

Platelet Aggregation1 trial

Elderly1 trial

Adult1 trial

Diabetes Mellitus1 trial

Hemodialysis1 trial

Prevention1 trial

Myocardial Infarction (MI)1 trial

Migraine1 trial

Acute Myocardial Infarction (AMI)1 trial

Unspecified9 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News